1. Home
  2. Analysis
  3. Gammagard
  4. Belbuca

Gammagard and Belbuca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Gammagard and Belbuca. Common interactions include migraine among females and fatigue among males.

The phase IV clinical study analyzes what interactions people who take Gammagard and Belbuca have. It is created by eHealthMe based on reports of 15 people who take Gammagard and Belbuca from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 26, 2022

15 people who take Gammagard and Belbuca together, and have interactions are studied.

What is Gammagard?

Gammagard has active ingredients of immune globulin. eHealthMe is studying from 7,343 Gammagard users for its effectiveness, alternative drugs and more.

What is Belbuca?

Belbuca has active ingredients of buprenorphine hydrochloride. eHealthMe is studying from 896 Belbuca users for its effectiveness, alternative drugs and more.

Number of Gammagard and Belbuca reports submitted per year:

Gammagard and Belbuca drug interactions.

Common Gammagard and Belbuca drug interactions by gender *:

female:

  1. Migraine
  2. Headache
  3. Infusion related reaction
  4. Blood urine present
  5. Dysuria
  6. Kidney infection
  7. Pyrexia
  8. Nausea
  9. Bronchitis
  10. Fall

male:

  1. Fatigue
  2. Headache
  3. Malaise
  4. Nausea
  5. Pain
  6. Pyrexia
  7. Rash
  8. Urticaria
  9. Infusion related reaction
  10. Chest discomfort

Common Gammagard and Belbuca drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Arthralgia
  2. Asthenia
  3. Influenza
  4. Infusion site pain
  5. Lethargy
  6. Limb injury
  7. Migraine
  8. Myalgia
  9. Nausea
  10. Oedema

60+:

n/a

Common conditions people have *:

  1. Immunodeficiency Common Variable: 11 people, 73.33%
  2. Lichen Myxoedematosus (deposition of acid mucopolysaccharides in the skin): 1 person, 6.67%
  3. Immunodeficiency: 1 person, 6.67%
  4. Dehydration (dryness resulting from the removal of water): 1 person, 6.67%
  5. B-Lymphocyte Abnormalities (abnormal population of b lymphocytes in the blood, bone marrow, or tissues): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Gammagard and Belbuca?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Gammagard and Belbuca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Gammagard side effects:

Browse all side effects of Gammagard:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Belbuca side effects:

Browse all side effects of Belbuca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Gammagard interactions:

Browse all interactions between Gammagard and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Belbuca interactions:

Browse all interactions between Belbuca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on immune globulin and buprenorphine hydrochloride (the active ingredients of Gammagard and Belbuca, respectively), and Gammagard and Belbuca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Gammagard and Belbuca.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.